Business · Companies · 6 hrs ago
Singapore seeks commercial success from its growing pharmaceutical sector
Singapore has attracted eight of the world’s top 10 drug makers as it works to become Southeast Asia’s leading biomedicine hub.
Experts say it needs commercially successful medicines to turn its scientific strengths into lasting gains.
The city state’s small home market and rising competition for investment are challenges.
Industry insiders say Singapore could become a gateway for Chinese medicines and a regional centre for rare-disease care.
Bayer hopes Singapore will be among the first places to approve its new blood thinner asundexian, which is intended to prevent repeat strokes.
China approved the medicine last month, and Bayer said on November 9 that the United States had also approved it.
Singapore has attracted major pharmaceutical manufacturers through investments and initiatives.
Industry experts say it needs to turn scientific strengths into commercially successful medicines.
They say the city state must also overcome the limits of its small domestic market as competition for investment intensifies.
Bayer hopes Singapore will be among the first places to approve its new blood thinner asundexian for preventing recurrent strokes.
China approved the medicine last month, and Bayer said the United States had approved it too.
- Who
- Singapore and pharmaceutical companies including Bayer.
- What
- Singapore is seeking commercial success from its pharmaceutical sector, while Bayer hopes the city state will be among the first to approve asundexian.
- When
- The article was published on November 22, 2026. China approved asundexian the previous month, and Bayer said on November 9 that the United States had approved it.
- Where
- Singapore; the article also refers to approvals in China and the United States.
- Why
- Singapore wants to strengthen its position as a biomedicine hub, but experts say it needs commercially successful medicines and must overcome the limits of its small domestic market.
This story does not have two clearly opposing sides.
Singapore has sought to become Southeast Asia’s premier biomedicine hub.
China approved Bayer’s asundexian, according to the article’s reference to approval last month.
Bayer said the United States had approved asundexian.
The article reported Bayer’s hope that Singapore would be among the first places to approve the medicine.
- Leading drug makers
- Singapore hosts 8 of the top 10 drug makers.
- Medicine
- Asundexian, Bayer’s new blood thinner for preventing recurrent strokes.
- China approval
- China approved asundexian the month before the article’s November 22, 2026 publication.
- US approval
- Bayer said the United States had approved asundexian on November 9, 2026.
- Singapore’s goal
- Become Southeast Asia’s premier biomedicine hub.